March 01, 2017 2:03 PM ET

Biotechnology

Company Overview of MediciNova, Inc.

Company Overview

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company’s product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. Its product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as no...

4275 Executive Square

Suite 650

La Jolla, CA 92037

United States

Founded in 2000

10 Employees

Phone:

858-373-1500

Fax:

858-404-0048

Key Executives for MediciNova, Inc.

Co-Founder, Chief Executive Officer, President and Executive Director
Age: 66
Total Annual Compensation: $518.9K
Chief Medical Officer
Age: 50
Total Annual Compensation: $344.7K
Head of Japanese Office and Vice President
Age: 48
Total Annual Compensation: $301.8K
Vice President
Age: 47
Total Annual Compensation: $257.0K
Compensation as of Fiscal Year 2015.

MediciNova, Inc. Key Developments

Medicinova, Inc. Provides Earnings Guidance for the Six Months Ending June 30, 2017 and the Year Ending December 31, 2017

MediciNova, Inc. provided earnings guidance for the six months ending June 30, 2017 and the year ending December 31, 2017. For the six months, the company reported operating loss of $6,460,000 and net loss of $6,460,000 or $0.18 per basic and diluted share. For the year, the company reported operating loss of $12,654,000 and net loss of $12,654,000 or $0.35 per basic and diluted share.

MediciNova Announces Positive Findings from Completed Trial of MN-166 (ibudilast) in Methamphetamine Dependence Presented at the 50th Winter Conference on Brain Research

MediciNova, Inc. announced the presentation of results from a completed Phase 1b trial of MN-166 (ibudilast) in methamphetamine dependence at a symposium titled “Neuroimmune Modulation in Addiction: Preclinical and Clinical Findings” at the 50thWinter Conference on Brain Research held from January 28 to February 2, 2017 in Big Sky, Montana. Major highlights from the presentation, “Clinical Development of Ibudilast for Methamphetamine Use Disorder,” include the following: Ibudilast increased levels of the biomarker brain-derived neurotrophic factor (BDNF), a growth factor which helps to support the survival of existing neurons and encourages the growth of new neurons and synapses, when compared to placebo; Ibudilast decreased levels of the biomarker tumor necrosis factor (TNFa), a pro-inflammatory cytokine, when compared to placebo (p=0.027); Ibudilast decreased levels of the biomarker vascular cell adhesion molecule (VCAM1), which mediates leukocyte-endothelial cell adhesion and signal transduction and may play a role in the development of neurodegenerative disorders, when compared to placebo (p=0.035); Ibudilast was safe and well tolerated during the methamphetamine infusions; Ibudilast is currently being investigated in a Phase 2 study to determine its ability to help methamphetamine users reduce or stop use altogether.

MediciNova, Inc., 2016 Earnings Call, Feb 15, 2017

MediciNova, Inc., 2016 Earnings Call, Feb 15, 2017

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact MediciNova, Inc., please visit medicinova.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.